SUPPLEMENTARY TABLES
. Data collection, refinement and validation statistics. Supplementary Table 7 . Ligands of CD11b and their affinities as reported in the literature.
Ligand K d (M) Method used
Platelet factor 4 (PF4) 1.3×10 -6 ± 0.2×10 -6 (9) BLI with immobilized PF4 and the I-domain in solution Hookworm-derived Neutrophil adhesion inhibitor (NIF) 1) 1×10 -9 (10) 2) 2.1×10 -9 ± 0.5×10 -9 (4) , K d2 and K d3 =10-100×10 -6 (12))
2) 4 binding events: K d1 = 0.1-0.5×10 -6 , K d2 and K d3 =10-100×10 -6 , K d4 =0.01×10 -6 (12) 1) SPR with immobilized LL-37 2) BLI with immobilized I-domain and LL-37 in solution Fibrinogen (Fg) 1) 2.2×10 -7 ± 0.6×10 -7 (13) 2) 2x10 -4 (14) 3) 2.5×10 (Figure 1d ). This pocket is ~15 Å away from the canonical phosphocholine binding pocket in other beta barrel pore forming toxins (19, 20) , which is occupied in all known LukGH structures by the side chain of M178.
We wanted to confirm the involvement of the individual residues of LukGH in oligomerisation and activity, and subsequently engineer LukGH that can oligomerise upon binding to moCD11b-I. We therefore generated a series of variants (Ala, natural variants and amino acid deletions, mainly in the LukH K319A background) and measured their activity (reported as EC 50 values or cell viability at a fixed cytotoxin concentration) towards differentiated granulocyte-like HL-60 cells and mouse neutrophils and also oligomerisation in presence of the recombinant receptors. All mutants were characterized by CD spectra and melting temperatures (T m ) to exclude false positive results due to protein instability ( Supplementary Figures 8 and 9 ). The mutants tested had T m values similar to the wild-type, except for the L68 and D69 variants (lower T m of D69 variants probably due to loss of stabilizing interactions with the adjacent β-sheet (Figure 2c) ). Oligomerisation of the LukG N33E LukH and LukG S30N LukH mutants could not be measured, as they showed increased aggregation when tested alone or in presence of human or mouse CD11b-I. Interestingly, the LukG D69A LukH K319A , LukG D69N LukH K319A , LukG D69E LukH K319A , LukG L68Q LukH K319A and LukG N71D LukH K319A variants, which tend to aggregate when incubated alone for up to 36 h at room temperature (Figure 3f ), were stabilized in complex with both human and mouse CD11b-I (Figure 3e, 3f) , as octamers or heterodimers, respectively.
The LukGH pore formation on resting cells is more enigmatic. The receptor density itself is only ~2-fold decreased compared to LPS-activated cells (21) , so it is presumably the presence of the closed conformation of the integrin I domain and the lack of clustering that limit activity. This scenario is likely less physiologically relevant at late infection time points, as the S. aureus extracellular components activate PMNs (21) , but may become relevant at the onset of the infection. Interestingly, the killing curves are particularly flat on insensitive PMNs (i.e. little dependency of killing on LukGH concentration) (21) , implying that LukGH concentration is not rate limiting in this process. In absence of any other stimuli, LukGH itself was shown to be able to prime PMNs (22) . It is thus possible that at early stages of the infection, (and LukGH is one of the earliest expressed leukocidins (23)), LukGH promotes an outsidein signaling with conversion of the integrin I domain to an open form, with binding occurring directly to the bent conformer followed by pore insertion.
Although LukGH oligomerisation in solution is a good predictor of cytolytic activity, i.e. no activity against mouse cells and no oligomerisation with the mouse receptor, the smaller surface area of the oligomeric interface in the human compared with the mouse complex, as found in the crystal structures, appears counter-intuitive. It is therefore tempting to speculate that flexibility on the outskirts of the interface is needed to promote oligomerisation (kinetically). This aspect must be considered when attempting to improve oligomerisation of LukGH towards a certain species based on the current structures. On the other hand, improving binding appears a much easier endeavor. Interestingly, the sequence conservation map of the interface (both on LukGH and CD11b-I side) also predicts higher conservation for residues forming the core of the interface, and higher diversity towards the edges (Supplementary Figure 10 ). In addition, the contact residues are not conserved between other CD11b integrins (CD11a, CD11c and CD11d), which explains the specificity of LukGH towards CD11b. comparing the frames, and discarding those displaying significant alterations. Data reduction to produce the final scattering profiles of the complexes were performed using standard methods. Briefly, for 2D-to-1D radial averaging the SASFLOW pipeline was used (25) . Scattering profiles from the buffer without protein were used for background subtraction.
SUPPLEMENTARY MATERIAL AND METHODS

Production of moCD11b-I variants and expression and purification
To exclude any dissociation process, the program OLIGOMER (26) was used to check if the fits could be improved by additionally allowing some volume fractions of the individual subunits. This was not the case.
To account for missing residues not resolved in the crystal structure the program CORAL (27) 
